Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
400 participants
Study Classification
OBSERVATIONAL
Study Start Date
2016-12-31
Study Completion Date
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a prospective, observational, cohort study of patients with a clinical diagnosis of diabetes who are undergoing clinically indicated kidney biopsy. The intent is to collect, process, and study kidney tissue and to harvest blood, urine and genetic materials to elucidate molecular pathways and link them to biomarkers that characterize those patients have a rapid decline in kidney function (\> 5 mL/min/1.73m2/year) from those with lesser degrees of kidney function change over the period of observation. High through-put genomic analysis associated with genetic and biomarker testing will serve to identify key potential therapeutic targets for DKD by comparing patients with rapid and slow progression patterns. Each participating clinical site will search for, consent, harvest the biopsy sample, and enroll the participants as required for the TRIDENT protocol.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PeRsOnalising Treatment Of Diabetic Nephropathy:
NCT03509454
Diabetes Mellitus, Type 1
Diabetes Complications
Diabetic Nephropathies
COMPLETED
A Study in Participants With Diabetic Kidney Disease
NCT01113801
Diabetic Kidney Disease
Diabetic Nephropathy
Diabetic Glomerulosclerosis
TERMINATED
PHASE2
Blood/Urine Markers for Drug Discovery for Renal Disease in Diabetes
NCT02580266
Diabetes Complications
WITHDRAWN
GLUcose Transport and REnalPROtection in Chronic Kidney Disease
NCT05998837
Chronic Kidney Disease
Diabetes Mellitus, Type 2
Hypertension
COMPLETED
PHASE2/PHASE3
Molecular Analysis of Diabetic Kidney Disease Biopsies
NCT04029402
Diabetic Nephropathies
Kidney Disease, Chronic
RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Progress in the area of diabetic kidney research leading to new therapeutics development has been very limited. Indeed, no new medicines indicated for the treatment of chronic kidney disease (CKD) have been approved since ARB's have become standard of care nearly 15 years ago. Several factors explain the limited progress including but not limited to; a) animal and cell culture models do not recapitulate human DKD b) human genetic studies so far have failed to identify reproducible genetic variants associated with DKD c) the clinical manifestation of DKD is heterogeneous and might have even changed since the original description d) DKD is a clinical diagnosis and it is not clear what percentage of patients have histological disease.
Laboratory mice have served as invaluable tools to understand human disease development. As mouse genetic tools became readily available, it enabled us to perform time and cell type specific gene manipulation in animals to generate disease models and to understand the contributions of specific pathways. Unfortunately, mouse models do not recapitulate human diabetic kidney disease as animals develop only early DKD lesions; mesangial expansion and mild albuminuria11. Most models do not develop arterial hyalinosis, tubulointerstitial fibrosis and declining glomerular filtration rate (GFR); hallmarks of progressive DKD. There are several fundamental differences in gene expression patterns and physiology of human and murine kidneys. Such differences may explain the lack of translatability between mice and humans of pharmacological approaches aimed at treating DKD. This seems to be a general trend in other disease areas as well (for example Alzheimer's disease), leading to a recent movement toward translational and clinical research with increasing reliance on human samples.
Human genetic studies made paradigm-shifting observations in relatively rare monogenic forms of kidney diseases (including polycystic kidney disease and focal segmental glomerulosclerosis). Diabetic CKD on the other hand follows a complex polygenic pattern. Currently, the most powerful method to define the genetics of complex diseases such as DKD is genome wide association (GWAS), where associations between polymorphisms and the disease state are tested. Prior studies indicate that for complex traits, such as DKD, genetic polymorphisms that are associated with disease state are localized to the non-coding region of the genome12,13. Moreover, the genetic architecture of diabetic kidney disease has not been characterized and several large collaborations are currently addressing this issue14. Thus, the next challenge is to define target genes, target cell types and the mode of dysregulation caused by non-coding snips (SNPs15). Such studies require large collection of human tissue samples from disease relevant organs.
Diabetic kidney disease (DKD) remains a clinical diagnosis. Subjects with CKD in the presence of diabetes and albuminuria are considered to have diabetic nephropathy. Such definition is used in clinical practice and in research studies including clinical trials. Studies performed in 1980 provide the basis for the practice16,17. Investigators stage DKD as a progressive disease, beginning with the loss of small amounts of albumin into the urine (30-300mg/day; known as the stage of microalbuminuria, high albuminuria, occult or incipient nephropathy), then larger amounts (\>300mg/day; known as macroalbuminuria, very high albuminuria or overt nephropathy), followed by progressive decline in kidney function (eGFR), renal impairment and ultimately ESRD 17-19. This paradigm has proved useful in clinical studies, especially in type 1 diabetes, for identifying cohorts at increased risk of adverse health outcomes. However, boundaries between stages of DKD are artificial and the relationship between urinary albumin excretion and adverse health outcomes is log-linear in clinical practice. Indeed, the American Diabetes Association recently abandoned staging of albuminuria (ACR) for a more-straightforward \[ACR \>30 mg/g, (albuminuria present); ACR \<30 mg/g (albuminuria absent)\] criterion. Moreover, many patients, and especially those with type 2 diabetes, do not follow this classical course in modern clinical practice. For example, many subjects with DKD do not manifest excessive urinary albumin loss20. Indeed, of the 28% of the UKPDS cohort who developed moderate to severe renal impairment, half did not have preceding albuminuria. In the Diabetes Control and Complications Trial (DCCT), of the 11% patients with type 1 diabetes who developed an eGFR\<60 ml/min/1.73m2, 40% never had experienced overt nephropathy21. In addition, most patients with microalbuminuria do not progressively exhibit an increase in urinary albumin excretion as in the classical paradigm with treatment-induced and spontaneous 'remission' of albuminuria widely observed22,23. Consequently, individuals with microalbuminuria may better be regarded as being at increased risk of developing progressive renal disease (as well as cardiovascular disease and other diabetic complications), rather than as actually having DKD per se. While over the last 40 years it became evident that the original description of DKD needs revision, no alternative criteria have emerged given the lack of solid data on the correlation between histopathological (gold standard) DKD diagnosis and clinical manifestations. It is also possible that, with the introduction of better glycemic control and anti-renin (RAAS) blockade, the disease has evolved necessitating new observational cohorts to understand the clinical disease course and manifestations.
Diabetic kidney disease presents with a variable rate of kidney function decline24. Data from large observational cohorts indicate that GFR decline frequently does not follow a linear course. Several groups are working on modeling GFR decline patterns in patients. Such studies contributed to emphasizing patients termed as "rapid progressors". There is no consensus definition for rapid progression. Many studies define rapid progressors as patients with greater than 3 cc/year GFR decrease but alternative cut points such as even 10 cc/year has also been used. Identification and clinical characterization of rapid progressors became the center of several large scale efforts as these are the patients who would likely need intensive clinical management25. Furthermore recent post-hoc analyses of the Diabetic Nephropathy (IDNT and RENAAL) studies indicate that clinical trial outcomes are mostly driven by a small number of subjects with unusually rapidly progressive GFR decline i.e. subjects that display characteristics of rapid progressors. While investigators are still awaiting accurate descriptions, biomarker and clinical descriptive studies have yielded several interesting observations. Albuminuria remains one of the strongest risk factor for "FDA-approved" (hard) renal outcomes; doubling of serum creatinine, dialysis or death. Indeed some of the latest studies indicate that using a 4 or a 6 variable model, that includes albuminuria, age, sex, serum phosphate, serum calcium and serum albumin has C-statistics score of 0.84-0.91 to predict ESRD 26,27. During the last years several new biomarkers have been identified that can potentially identify patients who are at increased risk for rapid loss of kidney function. For example blood and urinary levels of kidney injury molecule (KIM1) shows promise to identify patients who are at risk for kidney function decline. Recently, investigators showed that circulating levels of tumor necrosis factor receptor 1 and 2 levels can identify patients with rapidly declining renal function 28. While these markers are generating increased interest; the critical questions remains; why do some patients follow a rapid decline in kidney function?
Laboratory mice have served as invaluable tools to understand human disease development. As mouse genetic tools became readily available, it enabled us to perform time and cell type specific gene manipulation in animals to generate disease models and to understand the contributions of specific pathways. Unfortunately, mouse models do not recapitulate human diabetic kidney disease as animals develop only early DKD lesions; mesangial expansion and mild albuminuria11. Most models do not develop arterial hyalinosis, tubulointerstitial fibrosis and declining glomerular filtration rate (GFR); hallmarks of progressive DKD. There are several fundamental differences in gene expression patterns and physiology of human and murine kidneys. Such differences may explain the lack of translatability between mice and humans of pharmacological approaches aimed at treating DKD. This seems to be a general trend in other disease areas as well (for example Alzheimer's disease), leading to a recent movement toward translational and clinical research with increasing reliance on human samples.
Human genetic studies made paradigm-shifting observations in relatively rare monogenic forms of kidney diseases (including polycystic kidney disease and focal segmental glomerulosclerosis). Diabetic CKD on the other hand follows a complex polygenic pattern. Currently, the most powerful method to define the genetics of complex diseases such as DKD is genome wide association (GWAS), where associations between polymorphisms and the disease state are tested. Prior studies indicate that for complex traits, such as DKD, genetic polymorphisms that are associated with disease state are localized to the non-coding region of the genome12,13. Moreover, the genetic architecture of diabetic kidney disease has not been characterized and several large collaborations are currently addressing this issue14. Thus, the next challenge is to define target genes, target cell types and the mode of dysregulation caused by non-coding snips (SNPs15). Such studies require large collection of human tissue samples from disease relevant organs.
Diabetic kidney disease (DKD) remains a clinical diagnosis. Subjects with CKD in the presence of diabetes and albuminuria are considered to have diabetic nephropathy. Such definition is used in clinical practice and in research studies including clinical trials. Studies performed in 1980 provide the basis for the practice16,17. Investigators stage DKD as a progressive disease, beginning with the loss of small amounts of albumin into the urine (30-300mg/day; known as the stage of microalbuminuria, high albuminuria, occult or incipient nephropathy), then larger amounts (\>300mg/day; known as macroalbuminuria, very high albuminuria or overt nephropathy), followed by progressive decline in kidney function (eGFR), renal impairment and ultimately ESRD 17-19. This paradigm has proved useful in clinical studies, especially in type 1 diabetes, for identifying cohorts at increased risk of adverse health outcomes. However, boundaries between stages of DKD are artificial and the relationship between urinary albumin excretion and adverse health outcomes is log-linear in clinical practice. Indeed, the American Diabetes Association recently abandoned staging of albuminuria (ACR) for a more-straightforward \[ACR \>30 mg/g, (albuminuria present); ACR \<30 mg/g (albuminuria absent)\] criterion. Moreover, many patients, and especially those with type 2 diabetes, do not follow this classical course in modern clinical practice. For example, many subjects with DKD do not manifest excessive urinary albumin loss20. Indeed, of the 28% of the UKPDS cohort who developed moderate to severe renal impairment, half did not have preceding albuminuria. In the Diabetes Control and Complications Trial (DCCT), of the 11% patients with type 1 diabetes who developed an eGFR\<60 ml/min/1.73m2, 40% never had experienced overt nephropathy21. In addition, most patients with microalbuminuria do not progressively exhibit an increase in urinary albumin excretion as in the classical paradigm with treatment-induced and spontaneous 'remission' of albuminuria widely observed22,23. Consequently, individuals with microalbuminuria may better be regarded as being at increased risk of developing progressive renal disease (as well as cardiovascular disease and other diabetic complications), rather than as actually having DKD per se. While over the last 40 years it became evident that the original description of DKD needs revision, no alternative criteria have emerged given the lack of solid data on the correlation between histopathological (gold standard) DKD diagnosis and clinical manifestations. It is also possible that, with the introduction of better glycemic control and anti-renin (RAAS) blockade, the disease has evolved necessitating new observational cohorts to understand the clinical disease course and manifestations.
Diabetic kidney disease presents with a variable rate of kidney function decline24. Data from large observational cohorts indicate that GFR decline frequently does not follow a linear course. Several groups are working on modeling GFR decline patterns in patients. Such studies contributed to emphasizing patients termed as "rapid progressors". There is no consensus definition for rapid progression. Many studies define rapid progressors as patients with greater than 3 cc/year GFR decrease but alternative cut points such as even 10 cc/year has also been used. Identification and clinical characterization of rapid progressors became the center of several large scale efforts as these are the patients who would likely need intensive clinical management25. Furthermore recent post-hoc analyses of the Diabetic Nephropathy (IDNT and RENAAL) studies indicate that clinical trial outcomes are mostly driven by a small number of subjects with unusually rapidly progressive GFR decline i.e. subjects that display characteristics of rapid progressors. While investigators are still awaiting accurate descriptions, biomarker and clinical descriptive studies have yielded several interesting observations. Albuminuria remains one of the strongest risk factor for "FDA-approved" (hard) renal outcomes; doubling of serum creatinine, dialysis or death. Indeed some of the latest studies indicate that using a 4 or a 6 variable model, that includes albuminuria, age, sex, serum phosphate, serum calcium and serum albumin has C-statistics score of 0.84-0.91 to predict ESRD 26,27. During the last years several new biomarkers have been identified that can potentially identify patients who are at increased risk for rapid loss of kidney function. For example blood and urinary levels of kidney injury molecule (KIM1) shows promise to identify patients who are at risk for kidney function decline. Recently, investigators showed that circulating levels of tumor necrosis factor receptor 1 and 2 levels can identify patients with rapidly declining renal function 28. While these markers are generating increased interest; the critical questions remains; why do some patients follow a rapid decline in kidney function?
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Diabetic Nephropathies
Diabetic Glomerulosclerosis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Confirmed Diabetic Nephropathy
Patients undergoing a clinically indicated kidney biopsy with a history of diabetes who satisfy pre-specified criteria for diabetic nephropathy.
There is no intervention
Intervention Type
OTHER
There are no interventions
Confirmed Non-diabetic Nephropathy
Patients undergoing a clinically indicated kidney biopsy with a history of diabetes who fail pre-specified criteria for diabetic nephropathy.
There is no intervention
Intervention Type
OTHER
There are no interventions
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
There is no intervention
There are no interventions
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
There are no interventions
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Type 1 and 2 Diabetes by American Diabetes Association (ADA) criteria
* Willingness to comply with study requirements, including intention to fully participate in protocol-specified follow-up at a clinical study site
* Able to provide informed consent
* Adult participants
* Planned medically indicated kidney biopsy, prescribed by a practicing nephrologist
* Willingness to comply with study requirements, including intention to fully participate in protocol-specified follow-up at a clinical study site
* Able to provide informed consent
* Adult participants
* Planned medically indicated kidney biopsy, prescribed by a practicing nephrologist
Exclusion Criteria
* End Stage Renal Disease (ESRD), defined as chronic dialysis or kidney transplant
* History of receiving dialysis for more than 30 days prior to biopsy
* Institutionalized
* Solid organ or bone marrow transplant recipient at time of first kidney biopsy
* Less than 3-year life expectancy
* History of active alcohol and/or substance abuse that in the investigator's assessment would impair the subject's ability to comply with the protocol
* Unable to provide informed consent
* Evidence of active cancer requiring treatment, other than non-melanoma skin cancer
* History of receiving dialysis for more than 30 days prior to biopsy
* Institutionalized
* Solid organ or bone marrow transplant recipient at time of first kidney biopsy
* Less than 3-year life expectancy
* History of active alcohol and/or substance abuse that in the investigator's assessment would impair the subject's ability to comply with the protocol
* Unable to provide informed consent
* Evidence of active cancer requiring treatment, other than non-melanoma skin cancer
Minimum Eligible Age
18 Years
Maximum Eligible Age
100 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MOUNT SINAI HOSPITAL
OTHER
Sponsor Role
collaborator
University of North Carolina
OTHER
Sponsor Role
collaborator
Northwestern University
OTHER
Sponsor Role
collaborator
University of New Mexico
OTHER
Sponsor Role
collaborator
Stanford University
OTHER
Sponsor Role
collaborator
The University of Texas Health Science Center at San Antonio
OTHER
Sponsor Role
collaborator
Ohio State University
OTHER
Sponsor Role
collaborator
Yale University
OTHER
Sponsor Role
collaborator
Albert Einstein College of Medicine
OTHER
Sponsor Role
collaborator
Oregon Health and Science University
OTHER
Sponsor Role
collaborator
Lehigh Valley Health Network
OTHER
Sponsor Role
collaborator
University of Arkansas
OTHER
Sponsor Role
collaborator
University of Southern California
OTHER
Sponsor Role
collaborator
University of Virginia
OTHER
Sponsor Role
collaborator
Regeneron Pharmaceuticals
INDUSTRY
Sponsor Role
collaborator
Boehringer Ingelheim
INDUSTRY
Sponsor Role
collaborator
GlaxoSmithKline
INDUSTRY
Sponsor Role
collaborator
Gilead Sciences
INDUSTRY
Sponsor Role
collaborator
Juvenile Diabetes Research Foundation
OTHER
Sponsor Role
collaborator
Novo Nordisk A/S
INDUSTRY
Sponsor Role
collaborator
University of Pennsylvania
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Katalin Susztak, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pennsylvania
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Site Status
RECRUITING
University of Southern California
Los Angeles, California, United States
Site Status
ACTIVE_NOT_RECRUITING
Stanford University
Palo Alto, California, United States
Site Status
RECRUITING
Yale University
New Haven, Connecticut, United States
Site Status
RECRUITING
Northwestern University
Chicago, Illinois, United States
Site Status
RECRUITING
University of Michigan
Ann Arbor, Michigan, United States
Site Status
ACTIVE_NOT_RECRUITING
University of New Mexico
Albuquerque, New Mexico, United States
Site Status
RECRUITING
Mount Sinai Hospital
New York, New York, United States
Site Status
RECRUITING
Columbia University
New York, New York, United States
Site Status
ACTIVE_NOT_RECRUITING
Albert Einstein College of Medicine
The Bronx, New York, United States
Site Status
ACTIVE_NOT_RECRUITING
University of North Carolina
Chapel Hill, North Carolina, United States
Site Status
RECRUITING
Ohio State University
Columbus, Ohio, United States
Site Status
RECRUITING
Oregon Health & Science University
Portland, Oregon, United States
Site Status
RECRUITING
Lehigh Valley Health Network
Allentown, Pennsylvania, United States
Site Status
RECRUITING
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Site Status
RECRUITING
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
Site Status
RECRUITING
University of Virginia
Charlottesville, Virginia, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Townsend RR, Guarnieri P, Argyropoulos C, Blady S, Boustany-Kari CM, Devalaraja-Narashimha K, Morton L, Mottl AK, Patel U, Palmer M, Ross MJ, Sarov-Blat L, Steinbugler K, Susztak K; TRIDENT Study Investigators. Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study. Kidney Int. 2020 Jan;97(1):10-13. doi: 10.1016/j.kint.2019.09.020. No abstract available.
Reference Type
BACKGROUND
Abedini A, Zhu YO, Chatterjee S, Halasz G, Devalaraja-Narashimha K, Shrestha R, S Balzer M, Park J, Zhou T, Ma Z, Sullivan KM, Hu H, Sheng X, Liu H, Wei Y, Boustany-Kari CM, Patel U, Almaani S, Palmer M, Townsend R, Blady S, Hogan J, Morton L, Susztak K; TRIDENT Study Investigators. Urinary Single-Cell Profiling Captures the Cellular Diversity of the Kidney. J Am Soc Nephrol. 2021 Mar;32(3):614-627. doi: 10.1681/ASN.2020050757. Epub 2021 Feb 2.
Reference Type
RESULT
Palmer MB, Abedini A, Jackson C, Blady S, Chatterjee S, Sullivan KM, Townsend RR, Brodbeck J, Almaani S, Srivastava A, Avasare R, Ross MJ, Mottl AK, Argyropoulos C, Hogan J, Susztak K. The Role of Glomerular Epithelial Injury in Kidney Function Decline in Patients With Diabetic Kidney Disease in the TRIDENT Cohort. Kidney Int Rep. 2021 Feb 3;6(4):1066-1080. doi: 10.1016/j.ekir.2021.01.025. eCollection 2021 Apr.
Reference Type
RESULT
Hogan JJ, Owen JG, Blady SJ, Almaani S, Avasare RS, Bansal S, Lenz O, Luciano RL, Parikh SV, Ross MJ, Sharma D, Szerlip H, Wadhwani S, Townsend RR, Palmer MB, Susztak K, Mottl AK; TRIDENT Study Investigators. The Feasibility and Safety of Obtaining Research Kidney Biopsy Cores in Patients with Diabetes: An Interim Analysis of the TRIDENT Study. Clin J Am Soc Nephrol. 2020 Jul 1;15(7):1024-1026. doi: 10.2215/CJN.13061019. Epub 2020 Apr 27. No abstract available.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
824503
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study
NCT05897372
TERMINATED
PHASE2
Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes.
NCT01835678
COMPLETED
PHASE3
A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
NCT05901831
COMPLETED
PHASE3
Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects
NCT02981966
COMPLETED
PHASE4
Mechanism of SGLT2 Inhibition in the Kidney
NCT06291155
RECRUITING
PHASE4
Renal Impairment in Type 2 Diabetic Subjects
NCT00554450
COMPLETED
PHASE1
Renal Denervation in Diabetic Nephropathy
NCT01588795
COMPLETED
PHASE4
A Study of LY2928057 in Hemodialysis Participants
NCT01991483
COMPLETED
PHASE1
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
NCT05465317
COMPLETED
Study of LY3016859 in Participants With Diabetic Nephropathy
NCT01774981
COMPLETED
PHASE1/PHASE2
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes
NCT00976495
COMPLETED
PHASE2
The Expression of circANKRD36 as a New Biomarker of Diabetic Nephropathy
NCT05061459
UNKNOWN
Renin-Angiotensin and Fibrinolysis in Humans: Effect of Long-Term PDE5 Inhibition on Glucose Homeostasis
NCT01409993
TERMINATED
PHASE4
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
NCT01487109
COMPLETED
PHASE2
Prevention of Microvascular Complications in Overweight Diabetics With Surgery or Best Medicine
NCT02011178
WITHDRAWN
NA
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
NCT02540993
COMPLETED
PHASE3
Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
NCT04419467
COMPLETED
PHASE2
The Differential Effects of Diabetes Therapy on Inflammation
NCT02150707
COMPLETED
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
NCT05887817
ACTIVE_NOT_RECRUITING
PHASE4
PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria
NCT03168295
COMPLETED
PHASE4
Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study
NCT06954090
ENROLLING_BY_INVITATION
PHASE4
Biorepository of Biospecimen Samples in Matched Healthy Control Participants and Participants Diagnosed With Diabetic Kidney Disease, Chronic Kidney Disease, or Type 2 Diabetes
NCT05631119
COMPLETED
Use of Sitagliptin to Decrease Microalbuminuria
NCT02048904
TERMINATED
PHASE4
A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes
NCT04929379
ACTIVE_NOT_RECRUITING
PHASE2
Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial
NCT06094920
ENROLLING_BY_INVITATION
PHASE4